Subscribe To
ESPR / Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up
ESPR News
By Seeking Alpha
August 29, 2023
Esperion Therapeutics: Speculative Buy, Playing The $300 Million Milestone Litigation
Esperion reported Q2 bempedoic acid revenue of $20.3M; we expect the bempedoic acid to surpass the 2023 consensus numbers. The ongoing Daiichi litigat more_horizontal
By Zacks Investment Research
August 1, 2023
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares t more_horizontal
By GlobeNewsWire
July 15, 2023
Esperion to Report Second Quarter 2023 Financial Results on August 1
ANN ARBOR, Mich., July 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results befo more_horizontal
By Zacks Investment Research
May 10, 2023
Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up
Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tue more_horizontal
By Zacks Investment Research
May 9, 2023
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares t more_horizontal
By InvestorPlace
April 6, 2023
7 Very Undervalued Penny Stocks to Buy in April 2023
Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fract more_horizontal
By Benzinga
March 29, 2023
Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal
By Zacks Investment Research
March 17, 2023
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study d more_horizontal